基質(zhì)Gla蛋白(MGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Matrix Gla Protein (MGP)
MGLAP; GIG36; Cell growth-inhibiting gene 36 protein
- 編號SEB477Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍0.78-50ng/mL
- 靈敏度最小可檢測劑量小于等于0.29ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 3032 ¥ 4332 ¥ 19494 ¥ 36822 ¥ 303240
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測基質(zhì)Gla蛋白(MGP)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的基質(zhì)Gla蛋白(MGP)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 89-97 | 93 |
| EDTA plasma(n=5) | 84-103 | 98 |
| heparin plasma(n=5) | 88-97 | 93 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的基質(zhì)Gla蛋白(MGP)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中基質(zhì)Gla蛋白(MGP)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-95% | 96-103% | 78-96% | 91-104% |
| EDTA plasma(n=5) | 88-101% | 98-105% | 78-98% | 84-101% |
| heparin plasma(n=5) | 89-96% | 89-98% | 85-96% | 82-93% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將基質(zhì)Gla蛋白(MGP)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的基質(zhì)Gla蛋白(MGP)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的基質(zhì)Gla蛋白(MGP)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的基質(zhì)Gla蛋白(MGP)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB477Ra02 | 基質(zhì)Gla蛋白(MGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB477Ra01 | 基質(zhì)Gla蛋白(MGP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB477Ra02 | 基質(zhì)Gla蛋白(MGP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAB477Ra01 | 基質(zhì)Gla蛋白(MGP)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB477Ra71 | 基質(zhì)Gla蛋白(MGP)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAB477Ra81 | 基質(zhì)Gla蛋白(MGP)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| SEB477Ra | 基質(zhì)Gla蛋白(MGP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB477Ra | 基質(zhì)Gla蛋白(MGP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB477Ra01 | 基質(zhì)Gla蛋白(MGP)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Nephrology Dialysis Transplantation | Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells [PubMed: PMC3611891] |
| Maturitas. | Bone metabolism regulators and arterial stiffness in postmenopausal women [Pubmed: 23916080] |
| The Egyptian Rheumatologist | Osteoprotegerin (OPG) and Matrix Gla protein (MGP) in rheumatoid arthritis patients: Relation to disease activity [ScienceDirect: S1110116414000076] |
| Toxicology Reports | Canola and hydrogenated soybean oils accelerate ectopic bone formation induced by implantation of bone morphogenetic protein in mice [Researchgate:Source] |
| Lipids in Health and Disease | Markers of increased cardiovascular risk in patients with chronic kidney disease [Biomedcentral:Source] |
| Human & Veterinary Medicine | The behavior of circulating matrix Gla protein, matrix metalloproteinase-9 and nitrotyrosine in patients with varicose veins [Hvm:Source] |
| Pol Arch Med Wewn | Effect of Vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5 [PubMed: 26176325] |
| Lipids Health Dis. | Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study [pmc:PMC4739105] |
| Kidney Blood Press Res. | Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease [Pubmed:27100101] |
| Archives of?Oral?Biology | Matrix-Gla Protein rs4236 [A/G] gene polymorphism and serum and GCF levels of MGP in patients with subgingival dental calculus [pubmed:27348051] |
| Cell?Death?&?Disease | Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis [Pubmed:29880866] |
| Urology | High concentration of calcium promotes mineralization in NRK52E cells via inhibiting the expression of matrix Gla protein [Pubmed:29935264] |
| Clinica?Chimica?Acta | Serum total matrix Gla protein: Reference interval in healthy adults and variations in patients with vascular and osteoarticular diseases [Pubmed: 30597137] |
| Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients [Pubmed: 30847765] |
| Renal Failure | Relationship of matrix Gla protein and vitamin K with vascular calcification in hemodialysis patients [Pubmed: 31538831] |
| Heliyon | Matrix Gla protein maintains normal and malignant hematopoietic progenitor cells by interacting with bone morphogenetic protein-4 [Pubmed: 32322728] |
